Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 1300

PSA Screening for HIM Act

Rep. Dunn Introduces the PSA Screening for HIM Act to Eliminate Copays for Prostate Cancer Tests

This bill is currently in the early stages of the legislative process after being introduced in the House. It has been sent to the House Committee on Energy and Commerce for review. There are no upcoming votes scheduled at this time.

Legislative Progress

House
Senate
President
Law
Could go either way

The bill has support from both parties and addresses a clear health disparity, but it must still pass through committees and compete with other legislative priorities.

Key Points

HealthcareCivil Rights

Impact Analysis

Personal Impact

Life & Work

Small businesses offering group health plans would be required to include no-cost prostate cancer screenings for eligible employees. While this could marginally increase premiums, the cost is likely modest since PSA blood tests are inexpensive. On the positive side, early detection could reduce expensive late-stage treatment costs that drive up group plan premiums over time.

The cost of treating metastatic prostate cancer in the United States health care system is hundreds of millions of dollars more annually than the cost of treating localized, early-stage cancer.
2
2
2
5
0
ImpactCertaintyScopeDurationSentiment

Programs

Disabilities

Milestones

2 milestones2 actions
Feb 13, 2025House

Referred to the House Committee on Energy and Commerce.

Feb 13, 2025

Introduced in House

The bill was officially filed and given a number. It now enters the legislative queue.

Votes

No votes have been recorded for this legislation yet.

Source Information

Document Type

Congressional Bill

Official Title

PSA Screening for HIM Act

Bill NumberHR 1300
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the House Committee on Energy and Commerce.

Sponsor

Cosponsors

(36)
D: 29R: 7

Analysis generated by AI. Always verify with official sources.